NanoViricides (NNVC.OB) Offers Solid Year-End Results, Highlights Impressive Drug Pipeline
NanoViricides Inc. today announced it has filed its financial year-end annual report, citing its best financial position in its operating history. Nano Viricides is a development-stage company focused on special purpose nanomaterials for viral therapy, including drugs against viral diseases such as H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The company said its solid position is partially due to its ability to control operations and maintain low expenditures. Cash-in-hand estimates demonstrate the company to…